Find My Journal

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao, Lin Xu, Lin Wu, Yi Shen, Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Fei Ke, Xiaofei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Ke‐Neng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Hong‐Hong Yan, Xue‐Ning Yang, Qing Zhou, Yi‐Long Wu, Yi‐Long Wu, Qun Wang, Weimin Mao, Lin Wu, Yi Shen, Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Fei Ke, Xiaofei Li, Jian Li, Cheng Zhi Huang, Zhidong Liu, Shun Xu, Ke‐Neng Chen, Shidong Xu, Lunxu Liu, Ping Yu, Buhai Wang, Haitao Ma, Siyu Wang, Jian Hu, Wei Liu, Wěi Li, Jianhua Shi

The Lancet Oncology, 2017

Guangdong General Hospital, Guangdong Academy of Medical Sciences, The First Affiliated Hospital, Sun Yat-sen University, Zhongshan Hospital, Sun Yat-sen University, Fudan University, Zhejiang Cancer Hospital, First Hospital of China Medical University, China Medical University, Third Affiliated Hospital of Harbin Medical University, Harbin Medical University, Hunan Cancer Hospital, Qingdao University, Liaoning Cancer Hospital & Institute, Fujian Medical University, Union Hospital, Jilin Province Tumor Hospital, Jiangsu Cancer Hospital, Peking University People's Hospital, Peking University, Tongji University, Shanghai Pulmonary Hospital, Tang Du Hospital, Peking University First Hospital, Fujian Provincial Cancer Hospital, Beijing Chest Hospital, Peking University Cancer Hospital, West China Hospital of Sichuan University, Sichuan University, Sichuan Cancer Hospital, Northern Jiangsu People's Hospital, Soochow University, First Affiliated Hospital of Soochow University

Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

525

Citations

View on Google Scholar